23andMe Genetic Data Bids - Search News

Order byBest matchMost fresh

News

23andMe, Genetic

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.

Continue reading

A drug developer is buying 23andMe - what does that mean for your DNA data?

23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction

1hon MSN

23andMe and its user data will soon belong to a pharmaceutical giant

23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech ...

Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results